Table 3.
Incidence of adverse effects, VNRS for pain and patients received rescue drug up to 48 h after anesthesia
| Parameters | Group G (n = 40) |
Group R (n = 44) |
Group GR (n = 40) |
P value (overall) |
|---|---|---|---|---|
| Adverse effects | ||||
| Dizziness | 5 | 3 | 4 | 0.677 |
| Headache | 2 | 1 | 2 | 0.761 |
| Drowsiness | 1 | 0 | 1 | 0.572 |
| VNRS for postoperative pain | ||||
| postoperative 0–2 h | 6.4 ± 2.0 | 7.0 ± 2.0 | 6.3 ± 2.0 | 0.225 |
| postoperative 2–24 h | 3.2 ± 1.4 | 3.5 ± 1.5 | 3.3 ± 2.0 | 0.608 |
| Postoperative 24–48 h | 1.7 ± 1.0 | 1.9 ± 1.0 | 1.5 ± 1.4 | 0.180 |
| Rescue analgesic requirements | ||||
| postoperative 0–2 h | 8 (20.0%) | 11 (25.0%) | 9 (22.5%) | 0.861 |
| postoperative 2–24 h | 0 (0.0%) | 2 (4.5%) | 0 (0.0%) | 0.158 |
| Postoperative 24–48 h | 1 (2.5%) | 1 (2.3%) | 0 (0.0%) | 0.614 |
Data presented as mean ± SD or n (%) of patients
Group G, patients received oral gabapentin 300 mg 1 h before induction of anesthesia; Group R, patients received intravenous ramosetron 0.3 mg at the end of surgery; Group GR, patients received oral gabapentin 300 mg 1 h before induction of anesthesia and intravenous ramosetron 0.3 mg at the end of surgery; VNRS verbal numerical rating scale 0–10; 0 = no nausea, 10 = worst nausea